CELC NCCN Win: 16 Days to Category 1, Stock Says Sell

The FDA approved Celcuity’s REVTORPYK (gedatolisib) on July 14, 2026. Sixteen days later, the NCCN listed it as a preferred Category 1 second-line therapy for HR+/HER2- locally advanced or metastatic breast cancer without PIK3CA mutations. That is fast. The stock closed at $87.64 on July 30, the day of the announcement. That is down 18.5% from the $107.58 pre-approval close on July 10. The science keeps winning. The market keeps selling.

The initial approval and the sell-off were covered in a prior REVTORPYK analysis. The thesis was straightforward: VIKTORIA-1 data is exceptional, but a $4.3 billion market cap with zero revenue and no commercial infrastructure is pricing in a flawless launch. The NCCN inclusion is the first real evidence the launch can work. It is not enough to change the verdict, but it narrows the risk.

What NCCN Category 1 actually means

The NCCN is a 33-member alliance of leading cancer centers. Its guidelines drive prescribing decisions across US oncology. A “preferred Category 1” recommendation is the highest NCCN category: uniform consensus among panel members based on high-quality evidence. When a drug gets Category 1, oncologists do not need to justify the choice to payers as aggressively. It shortens the path from “FDA approved” to “routinely prescribed.”

The timing matters. A PubMed analysis of NCCN incorporation speed found a median of 19 days from FDA approval to NCCN guideline inclusion. REVTORPYK hit 16 days. That is at the fast end of the distribution. For comparison, drugs with weaker data or contested trial designs can wait months for guideline updates. The speed here reflects the strength of the VIKTORIA-1 data: a hazard ratio of 0.24 for the triplet (gedatolisib + palbociclib + fulvestrant) versus fulvestrant alone in a post-CDK4/6, post-endocrine population. Median PFS of 9.3 months versus 2.0 months. The NCCN Breast Cancer Guidelines v4.2026 now list the regimen alongside other second-line options.

This is a commercial signal, not just a regulatory one. Celcuity has no oncology sales force, no payer relations team, and no reimbursement track record. The NCCN listing does part of that work for them. It tells community oncologists that the experts at MD Anderson, Memorial Sloan Kettering, and Dana-Farber endorse this regimen. For a 155-person company in Minneapolis with a diagnostic lab background, that institutional credibility is not trivial.

The competition is not standing still

The PI3K inhibitor space has two approved competitors, and both are problematic for Celcuity in different ways.

Novartis’s Piqray (alpelisib) is the incumbent, and it is shrinking. Piqray generated $382 million in 2025 revenue, down 15% year-over-year. This was the second straight year of declining sales. Novartis attributed the decline to competition across all markets. Piqray is approved only for PIK3CA-mutated breast cancer. REVTORPYK is approved for the wild-type population, which is roughly 1.5x larger (about 60% of HR+/HER2- tumors are wild-type versus 40% mutated). Celcuity has the bigger addressable market. But a shrinking incumbent in the same drug class is not a bullish signal for the category.

Genentech’s Itovebi (inavolisib) is the more dangerous competitor. Approved October 10, 2024, inavolisib targets PIK3CA-mutated, endocrine-resistant, first-line breast cancer in combination with palbociclib and fulvestrant. The INAVO120 Phase 3 trial showed median PFS of 15.0 months versus 7.3 months for the placebo arm (HR 0.43, 95% CI 0.32-0.59, p<0.0001), with a 58% objective response rate. That is a strong number. Inavolisib is moving earlier in the treatment sequence, into the first-line setting for PIK3CA-mutated patients. If Celcuity files its planned sNDA for the PIK3CA mutant population in Q3 2026, it will compete head-to-head with inavolisib in that population. The VIKTORIA-1 mutant cohort showed 11.3 months median PFS for the gedatolisib doublet versus 5.6 months for alpelisib plus fulvestrant (HR 0.51). That is a win against Piqray, but inavolisib’s 15.0 months in an earlier-line setting is the number to beat.

The competitive picture is not simple. Gedatolisib has the broadest mechanism (all class I PI3K isoforms plus mTORC1/2), the best tolerability (2.3-3.1% discontinuation rate versus Piqray’s 21%), and the largest addressable population (wild-type). The tolerability gap is driven by hyperglycemia: 2.3% grade 3 in VIKTORIA-1 versus 36.6% grade 3/4 with alpelisib in SOLAR-1. Stomatitis was the most common adverse event (69.2% in the triplet arm, mostly grade 1/2, with 19.2% grade 3), and neutropenia was the largest grade 3/4 event in the triplet (62.3%, driven by the palbociclib backbone). But it is an IV infusion in a market dominated by oral drugs, and the commercial infrastructure does not exist yet. The NCCN listing helps. It does not solve the problem.

The effect-size comparison is worth a closer look. Inavolisib’s INAVO120 trial achieved a PFS delta of 7.7 months (15.0 minus 7.3) in a first-line PIK3CA-mutated population. Gedatolisib’s VIKTORIA-1 triplet achieved a PFS delta of 7.3 months (9.3 minus 2.0) in a later-line wild-type population. These are different populations and different settings, so direct comparison is imperfect. But the deltas are in the same range. Inavolisib has the advantage of being oral and first-line. Gedatolisib has the advantage of working in the wild-type population where no PI3K inhibitor is approved. The NCCN listing validates the wild-type opportunity, but inavolisib’s first-line positioning means it captures patients before they ever reach REVTORPYK’s second-line window.

The IV delivery issue is a real commercial headwind. Outpatient oncology has shifted toward oral drugs over the past decade because they reduce chair time, nursing costs, and infusion center burden. Piqray and inavolisib are both oral. Gedatolisib requires an IV infusion. Community oncology practices, where the majority of breast cancer patients are treated, may hesitate to add infusion capacity for a new drug unless the efficacy advantage is compelling. The VIKTORIA-1 data is compelling. But compelling data does not automatically overcome practice economics. This is where the NCCN Category 1 listing matters most: it gives community oncologists institutional cover to justify the infusion burden to payers and to their own practice managers.

What the stock price is telling you

CELC closed at $87.64 on July 30, 2026, per Polygon. Market cap is $4.27 billion. The stock is up modestly from the $82.27 low on July 28, but still down 18.5% from the pre-approval price.

Here is the analytical tension. The NCCN listing is a genuine positive catalyst. It de-risks the commercial launch by providing institutional endorsement before the drug is even available. Celcuity’s expanded access program is already enrolling patients, and commercial launch is expected in late Q3 2026. The sNDA for the PIK3CA mutant population is expected in Q3 2026, which would roughly double the addressable market if approved.

But the stock has not moved on the NCCN news. The July 30 close of $87.64 is essentially flat versus July 29 ($83.26). The market is treating the NCCN listing as expected, not surprising. That is the problem with pricing in perfection: good news that was already expected does not move the stock. Only unexpected good news does, and the only unexpected good news that matters now is prescription data showing adoption ahead of Piqray’s launch curve.

For a comp comparison, consider how other small-cap oncology launches have traded post-approval. The pattern is consistent: approval pop, sell-off as the market prices in commercialization risk, then a second leg determined by prescription data. The NCCN listing is the kind of early signal that can precede a positive prescription surprise. But it is not prescription data. It is a necessary condition for adoption, not a sufficient one.

The verdict

The NCCN Category 1 inclusion in 16 days is a real positive. It tells you the oncology community wants this drug. The VIKTORIA-1 data backs that desire with numbers that are not marginal. But Celcuity at $4.27 billion market cap with zero revenue is still pricing in a launch that has not started. The NCCN listing is one piece of the commercial puzzle. The two that matter: whether payers cover an IV-infusion drug at parity with oral competitors, and whether prescription data in Q4 2026 shows adoption ahead of Piqray’s declining launch curve.

The position from the prior REVTORPYK analysis holds: do not buy CELC at $87. The risk-reward is poor until prescription data arrives. If the stock pulls back to $65-70 on general market weakness, the NCCN endorsement makes the risk-reward more interesting. The science is ahead of the stock. The stock is ahead of the business. Wait for the business to catch up.

The catalyst to watch is the Q3 2026 sNDA filing for the PIK3CA mutant population. If approved there, gedatolisib becomes the first PI3K inhibitor cleared for both wild-type and mutant patients. That is a genuine differentiator against both Piqray and inavolisib. Until then, the NCCN listing is a reason to watch, not a reason to buy. Compare this to GSK’s Jideytro approval, where a $100 billion company with existing oncology channels turned an approval into a commercial launch within a week. Celcuity does not have that infrastructure. The NCCN listing is the closest thing it has to a shortcut.

Source: Celcuity NCCN press release | FDA approval announcement | NCCN Breast Cancer Guidelines